Fig 3.
Recurrence-free survival curves of the analyzed patients. (a) Patients in all stages were analyzed based on the level of HK2 expression. (b) Patients in all stages were analyzed based on the level of p-PDH expression. (c) Patients in all stages were analyzed based on combined expression of HK2 and p-PDH. (d) Patients in stage II and III were analyzed based on the level of HK2 expression. (e) Patients in stage II and III were analyzed based on the level of p-PDH expression. (f) Patients in stage II and III were analyzed based on combined expression of HK2 and p-PDH. *Statistically significant.